Dawn Matthews, CEO, presented results of ADMdx’s analysis of image data for a Phase II clinical trial of the drug rasagiline in Alzheimer’s disease patients at the Clinical Trials in Alzheimer’s Disease (CTAD) conference in San Diego. The trial was led by Dr. Jeffrey Cummings of the Lou Ruvo Center for Brain Health at the Cleveland Clinic, in collaboration with the Alzheimer’s Disease Cooperative Study (ADCS) and the Alzheimer’s Drug Discovery Foundation (ADDF). ADMdx’s analysis of FDG PET data showed that rasagiline favorably affected glucose metabolism in frontostriatal regions of the brain, meeting the study’s primary endpoint. Clinical results also showed improvements in Quality of Life and in cognition associated with executive function.
